Icon teams up with IBM to accelerate clinical trial startup

CRO giant Icon is working with IBM in hopes of making clinical trials more efficient, tapping the company's famed Watson technology with an eye on speeding up recruitment and site selection.

Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15

Catalent watched as some unfavorable currency trends sapped its fiscal year revenue growth, but the company closed out its transformational year with a major increase in profits that management said is a sign of things to come.

Britain's NHS signs off on inVentiv's consent tech

The U.K.'s National Health Service has approved the use of inVentiv Health's informed consent technology, another victory for the CRO's pioneering software.

PPD partners up to better track trial events

PPD has reached out to clinical trial software provider Cisys LifeSciences to get its hands on technology the company believes can improve the process by which investigators examine and adjudicate safety events.

WuXi looks to Japan for manufacturing growth

WuXi PharmaTech's small-molecule business won approval to produce drugs in Japan, extending the CRO's reach as it looks to beef up its manufacturing revenue.

Chinese drugmaker trades $200M for CDMO Cytovance

China's Shenzhen Hepalink Pharmaceutical signed a deal to acquire contract drugmaker Cytovance Biologics for $205.7 million in cash, buying into the U.S.'s burgeoning market for large-molecule treatments.

BioClinica opens an app umbrella to unite researchers

Clinical trial technology outfit BioClinica has created what it's calling an app exchange, looking for new software that can help physicians and drug developers through the company's cloud-based data service.

AMRI signs on to help Saneca develop opium-based drugs

Contract drugmaker AMRI signed a deal with Italy's Saneca Pharmaceuticals to collaborate on opium-derived treatments, pairing up with eyes on the U.S. market for controlled substances.

INC Research builds general medicine, CNS divisions with two EVP promotions

Leading CRO INC Research is boosting its upper echelon in the areas of general medicine and central nervous system R&D, promoting two key members.

WuXi inks lab testing pact with Chinese Lee's Pharm

Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.

CRO field's growth seen through R&D outsourcing, industry consolidation

Thanks to pharma's R&D cost-cutting efforts, the CRO industry will expand at nearly a 10% clip through 2019, a new report says, citing trends that many industry-watchers will find familiar.

Recipharm strikes development deal for RedHill's bacteria-fighter candidate

Swedish contractor Recipharm inked a deal with Israeli biotech RedHill Biopharma to produce the company's leading drug candidate for clinical trials and an expected commercial launch.

Germany lists 54 GVK suspensions as EU comes down on Indian CRO

A few months ago, the European Medicines Agency followed through on a threatened continental marketing halt affecting about 700 drugs in Indian CRO GVK Biosciences' generic lineup due to allegations of manipulated trial results. Now, Germany's regulators have suspended another 54 drugs tested by GVK in accordance with the EMA's recommendations.

India's Accutest Research Labs expands into Latin America

Accutest Research Laboratories moved to expand in Latin America, announcing on Monday that it is establishing offices and operations in Brazil.

Actelion taps DKSH to break into Asia

Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.

U.K. CRO conglomerate bags another testing outfit with eyes on toxicology

Concept Life Sciences, a CRO pieced together through a string of acquisitions, has inked a deal to acquire a toxicology-focused contractor, looking to expand its palate of drug development services.

Evotec's hybrid R&D model keeps revenue rolling

Germany's Evotec grew its revenue 37% in the first half of 2015, as its CRO-like business brought in cash to support the company's in-house R&D.

WuXi watches profits slip on its way to going private

Chinese CRO WuXi Pharma posted more soaring revenue in the second quarter, but some costly investments and currency issues drove down the company's profits as it prepares to go private.

INC's backers line up for a big Wall Street payday

The deep-pocketed outfits that helped take INC Research public last year are angling to cash in on the CRO's resulting success on the market, flipping shares in a secondary offering.

Accelovance adding 70 jobs in Wales after a big EU buy

U.S. CRO Accelovance is blueprinting a new site in Wales, planning to add 70 positions as it builds out its European ranks.